Sustained-release hydrophilic matrix tablets of zileuton: Formulation and in vitro/in vivo studies

Journal of Controlled Release

Volumn 45, Issue 3, 1997, Pages 249-256

  Qiu, Yihong ^a   Cheskin, Howard ^a   Briskin, Jackie ^a   Engh, Kevin ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Hydrophilic matrix; In vitro release; In vitro in vivo correlation; Sustained release; Zileuton

Indexed keywords

CROSCARMELLOSE SODIUM; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; LIPOXYGENASE INHIBITOR; MAGNESIUM STEARATE; METHYLCELLULOSE; POLYMER; ZILEUTON;

ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; DISSOLUTION; DOG; DRUG ABSORPTION; DRUG FORMULATION; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MATRIX TABLET; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RACEMIC MIXTURE; SUSTAINED RELEASE PREPARATION;

EID: 0031040295     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(96)01574-X     Document Type: Article

References (10)

1. K.A. Erdman, A high-performance liquid chromatographic method for the determination of the concentration ratio of the R- and S-enantiomers of zileuton in human plasma. Abbott Scientific Report, Abbott Laboratories, Abbott Park, IL, 1992.
2. R.A. Braeckman, K.A. Erdman and G.R. Granneman, Stereospecific pharmacokinetics of the 5-lipoxygenase inhibitor zileuton after Q8H and Q6H Dosing in the healthy volunteers. Pharm. Res. 9 (1992) S-315.
3. P. Veng-Pedersen, Model-independent method of analyzing input in linear pharmacokinetic systems having polyexponential impulse response. I. Theoretical analysis. J. Pharm. Sci. 69 (1980) 298-305.
4. N.A. Peppas, Analysis of Fickian and non-Fickian drug release from polymers. Pharm. Acta Helv. 60 (1985) 110-111.
5. J.E. Hogan, Hydroxypropylmethylcellulose sustained release technology. Drug Dev. Ind. Pharm. 15 (1989) 975-999.
6. Y. Qiu, H. Hui and H. Cheskin, Formulation development of sustained-release hydrophilic matrix tablets of zileuton. Pharm. Dev. Tech. (submitted for publication).
7. N. Katori, N. Aoyagi and T. Terao, Estimation of agitation intensity in the GI tract in humans and dogs based on in vitro/in vivo correlation. Pharm. Res. 12 (1995) 237-243.
8. J.B. Dressman and K. Yamada, Animal models for oral drug absorption. In: P.G. Welling, F.L. Tse and S.V. Dighe (Eds.) Pharmaceutical Bioequivalence, Marcel Dekker, New York, 1991, pp. 235-266.
9. L.J. Leeson, In vitro/in vivo correlations. Drug Inf. J. 29 (1995) 903-915.
10. J.P. Skelly et al., In vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms. Pharm. Res. 7 (1990) 975-982.